Biography
Dr. Mota Alvidrez is an Assistant Professor (Tenure track) in the Department of Pharmaceutical Sciences at the University of New Mexico College of Pharmacy. Dr. Mota Alvidrez is also a KL2-funded scholar from the NCATS in the Clinical and Translational Science Center at the University of New Mexico. Dr. Mota Alvidrez works in basic and translational research focusing on the consequences of diabetic disease in cardiovascular and metabolic function, particularly atherothrombosis. His research program focuses on understanding the molecular mechanisms that guide why diabetic patients have worst and accelerated vascular atherosclerosis with life-threatening complications in sex-specific disease progression. His research has helped develop the first diabetic, atherosclerotic, obese, and dyslipidemic rat model and a non-invasive, longitudinal pre-clinical SPECT/CT imaging tool to evaluate inflammation in atherosclerosis externally. Dr. Mota Alvidrez’s research program identifies timely and accurate preclinical diagnostic modalities in diabetic vasculopathy that can be translated to the clinic. His research program also focuses on identifying therapeutic targets, vascular drug delivery, and immunotherapies in the still unresolved and important biomedical problem of diabetic vasculopathy.
Personal Statement
"I am a physician scientist in the Department of Pharmaceutical Sciences at the University of New Mexico. As part of my scientific contributions, I developed the first diabetic-atherosclerotic-obese-dyslipidemic rat model. I also developed a non-invasive, longitudinal, pre-clinical SPECT/CT imaging tool to externally evaluate inflammation in atherosclerosis. My work has been supported by independent extramural research funds including by NCATS, NIGMS, NHLBI, Burroughs Welcome Fund, among multiple others. I am currently funded by an NIGMS Diversity Supplement as well as funded by a KL2 grant by NCATS. My research group is very well-funded by the College of Pharmacy, the Clinical and Translational Sciences Center and the NIH. Currently, my research group is made up by 1 PhD student, 2 visiting scholars and 1 undergraduate student). I have been recruited and elected to serve on American Heart Association (AHA), American Diabetes Association (ADA) and American Society for Investigative Pathology (ASIP) as actively participating in leadership positions. Furthermore, I have received recognition for my research accomplishments in Mexico and the US by multiple scientific societies. As an early career investigator, I promote a highly collaborative and translational research group with a high impact in the scientific community through innovative research. We aim to identify and study cutting-edge cardiometabolic pathology while fostering the next generation of scientists. My scientific career is devoted to basic and translational research aiming to understand the molecular mechanisms that guide diabetic patients with poor hyperglycemic control with life threatening complications with sex-specific disease progression like peripheral artery disease. My career objective is to identify efficient and accurate diagnostics and therapeutic targets that can be translated to the clinic in hepatic glucose metabolism regulation to prevent diabetic atherothrombotic events, leading cause of death worldwide. Our research program also aims to determine the mechanistic pathways that regulate smooth muscle cell function in atherosclerosis leading to life threatening complications like coronary artery disease and myocardial infraction. My research program also focuses in identifying therapeutic targets and vascular drug delivery and immunotherapies in the still unresolved and important biomedical problem of diabetic vasculopathy with 3 innovative and timely approaches:1) use of tissue specific knockout animal models with a focus in cardiovascular pathophysiology using translational small animal surgical approaches to mimic human conditions, 2) discovery of novel preventive and diagnostic cardiovascular serologic biomarkers of disease to translate preclinical point of care approaches in clinical pathology and laboratory medicine, 3) implementation of molecular imaging and immunobiology assays and techniques for parallel in vivo cardiovascular morphology/function and protein/mRNA assays ex vivo using the state-of-the-art metabolomics and lipidomic assessment in genetically modified small animal models."
Areas of Specialty
DiabetesVasculopathyType-2 Diabetes Metabolic Disease Lipid Metabolism""
Education
MD, MS, FAHA
Achievements & Awards
"Keynote at UACJ school of medicine 50-year Anniversary at CMEASIP Young Scientist Leadership AwardFellow of the American Heart Association (FAHA)Leadership Academy for Early Career FacultyHistochemical Society Nominated Council MemberADA Diabetes & Cardiovascular Disease Interest Group Early Career AwardMonga-Hans Junior Faculty Scholar Award PISA 2020UTSW Postdoctoral Summer Travel Award 2020, Experimental Biology 2020Histochemical Society Award, Experimental Biology 2020ASIP Sobel Award, American Society for Investigative Pathology 2023202320232022202220212021202020202019 Burroughs Wellcome Fund Collaborative Research Travel Grant, Burroughs Wellcome Fund 2018 Bronze Poster Award Presentation, American Society for Investigative Pathology 2018 Promoting Diversity in Science Trainee Travel Award, American Society for Investigative Pathology 2018 UNC Summer Undergraduate Programs Symposium Poster Presentation JudgeReviewer for 2018 Annual Biomedical Research Conference for Minority StudentsAJP Editor’s Pick Publication for July, American Journal of Pathology 201820182018 Conference Travel Presentation Award 2017-2018, UNC Center for Global Initiatives 2017 Annual Meeting Full Travel Scholarship, Society for Advancement of Chicanos/Hispanics and Native Americans 2017 Histochemical Society Annual Meeting Trainee Travel Award, American Society for Investigative Pathology 2017 Experimental Biology Travel Award, Intersociety Council for Pathology Information 2016 Postdoctoral Travel Award, UNC Chapel Hill Office of Postdoctoral Affairs 2016 Student Conference Award Program, University of New Mexico Career Services 2016 Young Talents Award, Universidad Autonoma de Ciudad Juarez 2016 Student Conference Award Program, University of New Mexico Career Services 2015 Young Talents Award, Universidad Autonoma de Ciudad Juarez 2014"
Key Publications
Journal Article
Mota Alvidrez, Roberto, I 2023 Restoring Glucose Balance: Conditional HMGB1 Knockdown Mitigates Hyperglycemia in A Streptozotocin Induced Mouse Mode Heliyon, vol. 10, Issue https://pubmed.ncbi.nlm.nih.gov/38187339/
Journal Article
Mota Alvidrez, Roberto, I 2023 High Dose of Metformin Decreases Susceptibility to Occlusive Arterial Thrombosis in Diabetic Mice J Pharm Pharmacol Res, vol. 7, Issue 4, 192-202 https://www.fortunejournals.com/articles/high-dose-of-metformin-decreases-susceptibility-to-occlusive.pdf
Journal Article
Mota Alvidrez, Roberto, I 2023 Inflammatory Atherosclerotic Plaque Identification by SPECT/CT Imaging of LFA-1 using [111In] In-DANBIRT in a Novel Dyslipidemic Rat Model Annals of Nuclear Medicine, vol. 37 https://link.springer.com/article/10.1007/s12149-023-01868-3
Languages
- English
- Spanish
- French
- Japanese
Research and Scholarship
Agency: NIH/NCATS KL2 ScholarTitle: Regulation of HMGB1 in hyperglycemia control in T2D progressionDates: 09/2023-This project looks to underpin the mechanistic pathways regulated by HMGB1 in hyperglycemia in T2D.Role: PI
Agency: NIH/NHLBI PRIDE FOCUS SRP AwardTitle: Role of cytosolic phospholipase A2 in atherosclerosisDates: 02/01/2022-01/31/2023This project studies the pathophysiologic role of cytosolic phospholipase activity in atherosclerosis.Role: PI
Agency: NIH/NIGMS R35 Diversity Research SupplementTitle: vWf-ADAMTS13 homeostasis in trauma-induced coagulopathyDates: 09/2022-06/2025This project studies the role of the vWf-ADAMTS13 axis in regulating trauma-induced coagulopathy.Role: PI
Agency: Pittsburgh Liver Research Center Pre-P&FTitle: Evaluation of HMGB1 KO glucose regulation in T2DDates: 03/2021-05/2023Project evaluates the ample role of HMGB1 in regulating glucose control in diabetes.Role: PI""